Your session is about to expire
← Back to Search
Treatment Sequence Group 3 for Healthy Subjects
Study Summary
This trial aims to compare how well a new tablet of fexofenadine HCl works when taken with or without water, to the traditional film-coated tablets of fexofenad
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are there any available slots for patients to participate in this clinical trial?
"Indeed, as per clinicaltrials.gov data, this study is actively seeking participants. The trial was first listed on February 23rd, 2024 and last modified on March 19th, 2024. It aims to enroll 25 patients at a single site."
Could individuals younger than 55 years old participate in this study?
"To be eligible for this research study, individuals aged between 18 and 55 can apply. It is noteworthy that there are separate trials available for those under 18 (70 trials) and over 65 (381 trials)."
What is the total number of people involved in this clinical trial?
"Affirmative. As per the details provided on clinicaltrials.gov, this particular medical trial is presently in the recruitment phase. The study was initially shared on February 23rd, 2024, and its latest update occurred on March 19th, 2024. This investigation aims to enroll a total of 25 participants at a single designated site."
What is the level of risk associated with Treatment Sequence Group 2 for individuals undergoing therapy?
"According to our evaluation at Power, Treatment Sequence Group 2 has been rated a 1 on the safety scale. This rating is attributed to the Phase 1 nature of the trial where there is minimal available data supporting both safety and efficacy."
Share this study with friends
Copy Link
Messenger